XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.

@article{Li2010XLFIII43AN,
  title={XLF-III-43, a novel coumarin-aspirin compound, prevents diabetic nephropathy in rats via inhibiting advanced glycation end products.},
  author={Hongyan Li and Xuguang Zheng and Hongbo Wang and Yi Zhang and Hongqi Xin and Xiaoguang Chen},
  journal={European journal of pharmacology},
  year={2010},
  volume={627 1-3},
  pages={340-7}
}
Advanced glycation end products (AGE) have been implicated in the pathogenesis of diabetic complications. The purpose of this study was to examine the novel coumarin-aspirin compound XLF-III-43 in the inhibition of AGE formation in diabetic nephropathy. In vitro analysis showed XLF-III-43 in a dose-dependent manner decreased glucose induced formation of glycation adducts on albumin and inhibited AGE-lysozyme crosslinking. The streptozotocin-induced diabetic rats were used to investigate the… CONTINUE READING
Highly Cited
This paper has 21 citations. REVIEW CITATIONS